Cerulean Reports Third Quarter 2015 Corporate Highlights and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q
November 17, 2015 1:18 PM ESTWedbush reiterated an Outperform rating on Cerulean Pharma (NASDAQ: CERU), and cut the price target to $9.00 (from $16.00), following the company's 3Q earnings report. CERU reported a net loss of $10.6M ($0.39/share), slightly above consensus of ($0.41).
Analyst David Nierengarten commented, "CERU reported a net... More
